# EDGAR Filing Document

**Accession Number:** 0001787400
**File Stem:** 0001140361-26-016407
**Filing Date:** 2026-4
**Character Count:** 4648
**Document Hash:** e04d4ecee6d3668bf7ba9c129e426e4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-016407.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001140361-26-016407

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nkarta, Inc.
- **CENTRAL INDEX KEY:** 0001787400
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474515206
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39370
- **FILM NUMBER:** 26889287

**BUSINESS ADDRESS:**
- **STREET 1:** 1150 VETERANS BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (925) 407-1049

**MAIL ADDRESS:**
- **STREET 1:** 1150 VETERANS BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

#### <br>

#### UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION <br> Washington, D.C. 20549

#### SCHEDULE 14A <br> Proxy Statement Pursuant to Section 14(a) of the <br> Securities Exchange Act of 1934
Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Under §240.14a-12

### NKARTA, INC.
(Name of Registrant as Specified In Its Charter)

#### <br>

#### Not applicable

------

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required <br> ☐ Fee paid previously with preliminary materials. <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

![](ny20064125x2_defa14aslide1.jpg)

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V92834-P46732 \*Please check the meeting materials for any special requirements for meeting attendance. NKARTA, INC. 1150 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080 NKARTA, INC. 2026 Annual Meeting Vote by June 9, 2026 11:59 PM ET You invested in NKARTA, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2026. Get informed before you vote View the Notice & Proxy Statement and 2025 Annual Report to stockholders online OR you can receive a free paper or email copy of the material(s) by making a request prior to May 27, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call toll-free 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting\* June 10, 2026 1:00 p.m., Pacific Time www.virtualshareholdermeeting.com/NKTX2026 Vote Before the Meeting at ProxyVote.com by June 9, 2026 11:59 PM ET

------

![](ny20064125x2_defa14aslide2.jpg)

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings". 1. Election of two directors to serve until the company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified: For All Ali Behbahani, M.D., M.B.A. Zachary Scheiner, Ph.D. 2. Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2026. For 3. Advisory approval of the compensation paid to the company's named executive officers, as disclosed in the proxy statement. For 4. Advisory vote on the frequency of future advisory votes on executive compensation. 1 Year NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Voting Items Board Recommends V92835-P46732

------